As described in Chap. 2.2.7, there is a large body of data indicating that vitiligo, at least distinct clinical subtypes of it, represents an immune-mediated inflam-matory disease. This concept is further corroborated by those patients who experience beneficial effects from anti-inflammatory and/or immunomodulatory treatment, for example, after therapy with corticosteroids or topical calcineurin inhibitors. In this view, different systemic imunomodulators have been proposed for the treatment of the diffuse form of the disease. Recently, the widely used a new class of immunomodulators in dermatology defined as biologics have been tested in vitiligo in a limited number of patients to assess their therapeutic potential in this disease.
KeywordsAlopecia Areata Vitiligo Patient Topical Calcineurin Inhibitor Depigmented Skin Active Vitiligo
- 6.Cara CJ, Pena AS, Sans M et al (2004) Reviewing the mechanism of action of thiopurine drugs: towards a new paradig in clinical practice. Med Sci Monit 10:247–254Google Scholar
- 22.Skurkovich S, Korotky NG, Shaova NM, Skurkovich B (2002) Successful anti-IFN therapy of alopecia, vitiligo, and psoriasis. Clin Immunol 103:S103Google Scholar
- 23.Skurkovich S, Skurkuvich B (2006) Inhibition of IFN-γ as a method of treatment of various autoimmune diseases, including skin disease. In: Numerof R, Dinarello CA, Asadullah K (eds) Cytokines as potential therapeutic targets for inflam-matory skin diseases. Ernst Schering Research Foundation Workshop 58, Springer, Berlin, pp 1–27Google Scholar